Month: June 2024

HOUSTON, June 26, 2024 (GLOBE NEWSWIRE) — Cannabis Bioscience International Holdings (OTCMKTS: CBIH) is thrilled to introduce the groundbreaking strategies formulated by its freshly appointed Treasurer and Director, Mr. John Jones, who has facilitated a series of insightful discussions and established official communications between CBIH and a pioneering company in innovative product and packaging solutions for globally recognized brands. As CBIH prepares for the manufacturing and distribution of its products, the potential collaboration might involve this entity acting as CBIH’s product distributor, utilizing its expertise across various sectors such as retail, industrial packaging, manufacturing, production management, product marketing, fulfillment services, design services, and inventory management. Our research and product...

Bagsværd, Denmark, 26 June 2024 – Novo Nordisk today announced that the CLARION-CKD phase 3 trial failed to meet its primary endpoint and that it will recognise an impairment loss of around DKK 5.7 billion related to the intangible asset ocedurenone in the second quarter of 2024. Novo Nordisk acquired ocedurenone from KBP Biosciences PTE., Ltd. in 2023. The phase 3 lead indication trial CLARION-CKD, which investigated ocedurenone in patients with uncontrolled hypertension and advanced chronic kidney disease, was conducted by KBP Biosciences. The trial design included a prespecified interim analysis after all trial participants had completed 12 weeks of treatment. Based on the interim analysis, an independent data monitoring committee concluded that the trial met the prespecified futility criteria – meaning that the trial did not...

Company announcementfor ROCKWOOL A/SRelease no. 36 – 2024to Nasdaq Copenhagen         26 June 2024 New employee-elected Board member in ROCKWOOL A/S Today a by-election has been held for a Group-elected employee representative of the Board of Directors in ROCKWOOL A/S. The employees of ROCKWOOL have chosen that Janni Munkholm Nielsen shall represent them for the remaining election period until the Annual General Meeting in 2026, where new elections for employee-elected Board members will take place. Janni Munkholm Nielsen now joins, Connie Enghus Theisen and Christian Westerberg, as employee-elected Board members in ROCKWOOL A/S. Further information:         Kim Junge AndersenSenior Vice President, CFOROCKWOOL A/S+45 46 55 80 15AttachmentSE-2024-36_EN

June 26, 2024, Oslo, Norway: PGS held its Annual General Meeting today. The Annual General Meeting resolved to approve all matters as proposed in the Calling Notice. The minutes from the Annual General Meeting can be downloaded from www.newsweb.no or www.pgs.com.AttachmentGenforsprotokoll-AGM 2024

LAKEWOOD, N.J., June 26, 2024 (GLOBE NEWSWIRE) — Reliance Global Group, Inc. (Nasdaq: RELI; RELIW) (“Reliance”, “we” or the “Company”) today announced that the Company’s Board of Directors approved a 1-for-17 reverse stock split (the “Reverse Stock Split”) of the Company’s common stock (the “Common Stock”) in order to regain compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market (Rule 5550(a)(2)). The Company was not required to obtain shareholder approval to effectuate the Reverse Stock Split. The Company filed articles of amendment to the Company’s articles of incorporation, as amended, with the Secretary of State of the State of Florida to effectuate the Reverse Stock Split as of 5:00 p.m. Eastern Time on June 28, 2024. The Common Stock will begin trading on The Nasdaq Capital...

Infintium’s advanced hydrogen fuel cell technologies for material handling vehicles bring carbon-free and clean power source to major automotive, industrial, and retail companies Corporate net zero commitments expected to propel hydrogen powered heavy duty truck adoption Aurora, IL and Greer, SC, June 26, 2024 (GLOBE NEWSWIRE) — Goldenstone Acqusition Limited (“Goldenstone”), (NASDAQ: GDST), a Delaware blank check company, today announced that it and Infintium Fuel Cell Systems, Inc. (“Infintium” or the “Company”), a Greer, South Carolina based hydrogen fuel cell technology provider to some of the world’s largest commercial, industrial and retail companies, have entered into a definitive business combination agreement (the “Business Combination Agreement,” and the transactions contemplated thereunder, collectively, the “Business...

DALLAS, June 26, 2024 (GLOBE NEWSWIRE) — Texas Capital Bancshares, Inc. (NASDAQ: TCBI), the parent company of Texas Capital, today announced it will open a new financial center in Southlake, Texas next month. It will be the first location of its kind for the firm, transforming its retail strategy to meet the evolving needs of the clients within the markets it serves across Texas. The Southlake Financial Center will be located at 1538 East Southlake Boulevard in the heart of the Southlake Town Square alongside State Highway 114. As part of Texas Capital’s firm-wide transformation, the new location will advance the firm’s commitment to delivering relationship-focused, elevated client experiences. The location was designed to complement digital capabilities with the in-person experience that provides access to the firm’s private wealth...

Lengthens Patent Exclusivity of Plogosertib until August 2040 BERKELEY HEIGHTS, N.J., June 26, 2024 (GLOBE NEWSWIRE) — Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative medicines based on cancer cell biology, today announced the receipt of a notice from the European Patent Office of the intention to grant a patent which includes claims to novel pharmaceutical compositions of plogosertib, a PLK1 inhibitor. Once granted, the European patent will provide exclusivity until August 2040 not including any extensions. The Company is prosecuting patent applications from the same family in other jurisdictions. “The notice further strengthens the Company’s patent portfolio and attests to the novelty of Cyclacel’s clinical...

DALLAS, June 26, 2024 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system (CNS), today announced the pricing of an underwritten public offering of 14,361,113 shares of its common stock at a price to the public of $2.25 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 18,972,221 shares of its common stock at an offering price of $2.249 per pre-funded warrant, in each case before underwriting discounts and commissions. All of the securities are being offered by Taysha. In addition, Taysha has granted the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered...